Citations (125)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Youn Young Shim, Ji Hye Kim, Jae Youl Cho & Martin J. T. Reaney. (2022) Health benefits of flaxseed and its peptides (linusorbs). Critical Reviews in Food Science and Nutrition 0:0, pages 1-20.
Read now
Read now
Peter Norman. (2014) Spleen tyrosine kinase inhibitors: a review of the patent literature 2010 – 2013. Expert Opinion on Therapeutic Patents 24:5, pages 573-595.
Read now
Read now
Morten A. Karsdal, Anne Christine Bay-Jensen, Diana Julie Leeming, Kim Henriksen & Claus Christiansen. (2013) Quantification of “end products” of tissue destruction in inflammation may reflect convergence of cytokine and signaling pathways – implications for modern clinical chemistry. Biomarkers 18:5, pages 375-378.
Read now
Read now
Kamal D. Puri, Julie A. Di Paolo & Michael R. Gold. (2013) B-Cell Receptor Signaling Inhibitors for Treatment of Autoimmune Inflammatory Diseases and B-Cell Malignancies. International Reviews of Immunology 32:4, pages 397-427.
Read now
Read now
Jorge Morales-Torres. (2012) The status of fostamatinib in the treatment of rheumatoid arthritis. Expert Review of Clinical Immunology 8:7, pages 609-615.
Read now
Read now
Susanne Müller & Stefan Knapp. (2010) Targeting kinases for the treatment of inflammatory diseases. Expert Opinion on Drug Discovery 5:9, pages 867-881.
Read now
Read now
D. J. Sweeny, W. Li, E. Grossbard & D. T.W. Lau. (2010) Contribution of gut bacteria to the metabolism of the spleen tyrosine kinase (Syk) inhibitor R406 in cynomolgus monkey. Xenobiotica 40:6, pages 415-423.
Read now
Read now
Paolo Ruzza, Barbara Biondi & Andrea Calderan. (2009) Therapeutic prospect of Syk inhibitors. Expert Opinion on Therapeutic Patents 19:10, pages 1361-1376.
Read now
Read now
Malini Bajpai, Puneet Chopra, Sunanda G Dastidar & Abhijit Ray. (2008) Spleen tyrosine kinase: a novel target for therapeutic intervention of rheumatoid arthritis. Expert Opinion on Investigational Drugs 17:5, pages 641-659.
Read now
Read now
Martin Braddock. (2007) 11th Annual Inflammatory and Immune Diseases Drug Discovery and Development Summit. Expert Opinion on Investigational Drugs 16:6, pages 909-917.
Read now
Read now
Marina Ulanova, Florentina Duta, Lakshmi Puttagunta, Alan D Schreiber & A Dean Befus. (2005) Spleen tyrosine kinase (Syk) as a novel target for allergic asthma and rhinitis. Expert Opinion on Therapeutic Targets 9:5, pages 901-921.
Read now
Read now
Brian R Wong. (2005) Cambridge Healthtech Institute Signal Transduction Conference: Targets for Effective Therapeutics. Expert Opinion on Investigational Drugs 14:2, pages 209-214.
Read now
Read now
Articles from other publishers (113)
Guang Huang, Devon Hucek, Tomasz Cierpicki & Jolanta Grembecka. (2023) Applications of oxetanes in drug discovery and medicinal chemistry. European Journal of Medicinal Chemistry 261, pages 115802.
Crossref
Crossref
Zhaozhao Wang, Shu Qu, Jiahao Yuan, Wen Tian, Jinglei Xu, Rui Tao, Shilong Sun, Tao Lu, Weifang Tang & Yong Zhu. (2023) Review and prospects of targeted therapies for Spleen tyrosine kinase (SYK). Bioorganic & Medicinal Chemistry 96, pages 117514.
Crossref
Crossref
Xiao-Jing Ling, Ji-Fu Wei & Ying Zhu. (2023) Aiming to IgE: Drug development in allergic diseases. International Immunopharmacology 121, pages 110495.
Crossref
Crossref
Tamás Németh, Lili Balogh, Eszter Káposztás, Kata P. Szilveszter & Attila Mócsai. (2023) Neutrophil-Specific Syk Expression Is Crucial for Skin Disease in Experimental Epidermolysis Bullosa Acquisita. Journal of Investigative Dermatology 143:7, pages 1147-1156.
Crossref
Crossref
Rakesh Sahu, Kamal Shah, Yash Gautam & Kaushilya Sahu. (2023) Pyrazine Moiety: Recent Developments in Cancer Treatment. Current Organic Chemistry 27:10, pages 821-843.
Crossref
Crossref
Bachir Latli, Matt J. Hrapchak, Lalith P. Samankumara, Daniel R. Fandrick, Scott Pennino, Heewon Lee & Jinhua J. Song. (2023) Synthesis of BI 894416 and BI 1342561, two potent and selective spleen tyrosine kinase inhibitors, labeled with carbon 14 and with deuterium. Journal of Labelled Compounds and Radiopharmaceuticals 66:4-6, pages 155-168.
Crossref
Crossref
Saskia Carstensen, Ewald Benediktus, Tobias Litzenburger, Jens M. Hohlfeld & Meike Müller. (2021)
Basophil activation test: Assay precision and
BI
1002494
SYK
inhibition in healthy and mild asthmatics
. Cytometry Part A 101:1, pages 86-94.
Crossref
Crossref
Yoshiya Tanaka, David Millson, Shigeru Iwata & Shingo Nakayamada. (2021) Safety and efficacy of fostamatinib in rheumatoid arthritis patients with an inadequate response to methotrexate in phase II OSKIRA-ASIA-1 and OSKIRA-ASIA-1X study. Rheumatology 60:6, pages 2884-2895.
Crossref
Crossref
Sameer P. Kawatkar, Bernard Barlaam, Paul Kemmitt, Iain Simpson, David Watson, Peng Wang, Scott Lamont, Qibin Su, Scott Boiko, Timothy Ikeda, Joe Patel, Andy Pike, Hannah Pollard, Jon Read, Ujjal Sarkar, Haiyun Wang, Quanshan Wen, Zhiyuan Yan, James E. Dowling, Hannah Dry & Scott D. Edmondson. (2020) Identification of a novel series of azabenzimidazole-derived inhibitors of spleen tyrosine kinase. Bioorganic & Medicinal Chemistry Letters 30:18, pages 127393.
Crossref
Crossref
Yuanyuan Ding, Chaomei Li, Yongjing Zhang, Pengyu Ma, Tingting Zhao, Delu Che, Jiao Cao, Jue Wang, Rui Liu, Tao Zhang & Langchong He. (2020) Quercetin as a Lyn kinase inhibitor inhibits IgE-mediated allergic conjunctivitis. Food and Chemical Toxicology 135, pages 110924.
Crossref
Crossref
Cheng Wang, Xin Wang, Yao Li, Tianqi Wang, Zhi Huang, Zhongxiang Qin, Shengyong Yang, Rong Xiang & Yan Fan. (2020) Design and optimization of orally spleen tyrosine kinase (SYK) inhibitors for treatment of solid tumor. Bioorganic Chemistry 95, pages 103547.
Crossref
Crossref
Ana Martinez & Carmen Gil. 2019. Emerging Drugs and Targets for Multiple Sclerosis. Emerging Drugs and Targets for Multiple Sclerosis
170
196
.
Cesar Ramirez Molina, Sidsel Falkencrone, Per S. Skov, Edward Hooper‐Greenhill, Mike Barker & Marion C. Dickson. (2019) GSK2646264, a spleen tyrosine kinase inhibitor, attenuates the release of histamine in ex vivo human skin. British Journal of Pharmacology 176:8, pages 1135-1142.
Crossref
Crossref
Xia Bian, Liting Wu, Liangliang Mu, Xiaoxue Yin, Xiufang Wei, Xiaofang Zhong, Yanjian Yang, Junru Wang, Yuan Li, Zheng Guo & Jianmin Ye. (2018) Spleen tyrosine kinase from Nile tilapia (Oreochromis niloticus): Molecular characterization, expression pattern upon bacterial infection and the potential role in BCR signaling and inflammatory response. Fish & Shellfish Immunology 82, pages 162-172.
Crossref
Crossref
Michele Biagioli, Andrea Mencarelli, Adriana Carino, Sabrina Cipriani, Silvia Marchianò, Chiara Fiorucci, Annibale Donini, Luigina Graziosi, Franco Baldelli, Eleonora Distrutti, Gabriele Costantino & Stefano Fiorucci. (2018) Genetic and Pharmacological Dissection of the Role of Spleen Tyrosine Kinase (Syk) in Intestinal Inflammation and Immune Dysfunction in Inflammatory Bowel Diseases. Inflammatory Bowel Diseases 24:1, pages 123-135.
Crossref
Crossref
Toshinobu Kato, Takeshi Ohta, Hidenori Iwasaki, Hatsue Kobayashi, Akira Matsuo, Takahiro Hata & Mutsuyoshi Matsushita. (2017) JTE-852, a novel spleen tyrosine kinase inhibitor, blocks immunoglobulin G-mediated cellular responses and autoimmune reactions in vivo. Life Sciences 191, pages 166-174.
Crossref
Crossref
Anje A. te Velde. (2017) The C-Type Lectin Mincle: Clues for a Role in Crohn’s Disease Adjuvant Reaction. Frontiers in Immunology 8.
Crossref
Crossref
Woo-Ri Jo & Hye-Jin Park. (2017) Antiallergic effect of fisetin on IgE-mediated mast cell activation in vitro and on passive cutaneous anaphylaxis (PCA). The Journal of Nutritional Biochemistry 48, pages 103-111.
Crossref
Crossref
Peter A. Tauber & Winfried F. Pickl. (2017) Pharmacological targeting of allergen-specific T lymphocytes. Immunology Letters 189, pages 27-39.
Crossref
Crossref
Maninder Kaur, Manjinder Singh & Om Silakari. (2017) Oxindole-based SYK and JAK3 dual inhibitors for rheumatoid arthritis: designing, synthesis and biological evaluation. Future Medicinal Chemistry 9:11, pages 1193-1211.
Crossref
Crossref
Toshinobu Kato, Hidenori Iwasaki, Hatsue Kobayashi, Naoki Miyagawa, Akira Matsuo, Takahiro Hata & Mutsuyoshi Matsushita. (2017) JTE-852, a novel spleen tyrosine kinase inhibitor, blocks mediator secretion from mast cells with immunoglobulin E crosslinking. European Journal of Pharmacology 801, pages 1-8.
Crossref
Crossref
Hye-Jin Park. (2017) Anti-allergic and anti-inflammatory activity of Phellinus linteus grown on Panax ginseng. Food Science and Biotechnology 26:2, pages 467-472.
Crossref
Crossref
Srini Ramanathan, Julie A. Di Paolo, Feng Jin, Lixin Shao, Shringi Sharma, Michelle Robeson & Brian P. Kearney. (2016) Pharmacokinetics, Pharmacodynamics, and Safety of Entospletinib, a Novel pSYK Inhibitor, Following Single and Multiple Oral Dosing in Healthy Volunteers. Clinical Drug Investigation 37:2, pages 195-205.
Crossref
Crossref
Adriana Borriello, Ilaria Caldarelli, Debora Bencivenga, Emanuela Stampone, Silverio Perrotta, Adriana Oliva & Fulvio Della Ragione. (2016) Tyrosine kinase inhibitors and mesenchymal stromal cells: effects on self-renewal, commitment and functions. Oncotarget 8:3, pages 5540-5565.
Crossref
Crossref
Betty Lam, Yasuyoshi Arikawa, Joshua Cramlett, Qing Dong, Ron de Jong, Victoria Feher, Charles E. Grimshaw, Pamela J. Farrell, Isaac D. Hoffman, Andy Jennings, Benjamin Jones, Jennifer Matuszkiewicz, Joanne Miura, Hiroshi Miyake, Srinivasa Reddy Natala, Lihong Shi, Masashi Takahashi, Ewan Taylor, Corey Wyrick, Jason Yano, Jonathan Zalevsky & Zhe Nie. (2016) Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK). Bioorganic & Medicinal Chemistry Letters 26:24, pages 5947-5950.
Crossref
Crossref
Carlos J. Bosques & Anthony M. Manning. (2016) Fc-gamma receptors: Attractive targets for autoimmune drug discovery searching for intelligent therapeutic designs. Autoimmunity Reviews 15:11, pages 1081-1088.
Crossref
Crossref
Juyoung Shim, Rachel H. Kennedy, Lisa M. Weatherly, Lee M. Hutchinson, Jonathan H. Pelletier, Hina N. Hashmi, Kayla Blais, Alejandro Velez & Julie A. Gosse. (2016) Arsenic inhibits mast cell degranulation via suppression of early tyrosine phosphorylation events. Journal of Applied Toxicology 36:11, pages 1446-1459.
Crossref
Crossref
Sumit Kunwar, Ashok Raj Devkota & Dipesh K. C. Ghimire. (2016) Fostamatinib, an oral spleen tyrosine kinase inhibitor, in the treatment of rheumatoid arthritis: a meta-analysis of randomized controlled trials. Rheumatology International 36:8, pages 1077-1087.
Crossref
Crossref
Gregory D. Ferguson, Mercedes Delgado, Veronique Plantevin-Krenitsky, Kristen Jensen-Pergakes, R. J. Bates, Sanaa Torres, Maria Celeridad, Heather Brown, Kelven Burnett, Lisa Nadolny, Lida Tehrani, Garrick Packard, Barbra Pagarigan, Jason Haelewyn, Trish Nguyen, Li Xu, Yang Tang, Matthew Hickman, Frans Baculi, Steven Pierce, Keiji Miyazawa, Pilgrim Jackson, Philip Chamberlain, Laurie LeBrun, Weilin Xie, Brydon Bennett & Kate Blease. (2016) A Novel Triazolopyridine-Based Spleen Tyrosine Kinase Inhibitor That Arrests Joint Inflammation. PLOS ONE 11:1, pages e0145705.
Crossref
Crossref
Paul Martin, Michael Gillen, David Millson, Stuart Oliver, Clive Brealey, Robert Elsby, Muhammad Baluom, David Lau & Tim Mant. (2015) Effects of Fostamatinib on the Pharmacokinetics of Digoxin (a P-Glycoprotein Substrate): Results From in Vitro and Phase I Clinical Studies. Clinical Therapeutics 37:12, pages 2811-2822.
Crossref
Crossref
Guray Can, Suleyman Ayvaz, Hatice Can, Selim Demirtas, Hasan Aksit, Bulent Yilmaz, Ugur Korkmaz, Mevlut Kurt & Turan Karaca. (2015) The Syk Inhibitor Fostamatinib Decreases the Severity of Colonic Mucosal Damage in a Rodent Model of Colitis. Journal of Crohn's and Colitis 9:10, pages 907-917.
Crossref
Crossref
Jang-Sik Choi, Hae-jun Hwang, Se-Won Kim, Byung Il Lee, Jaekyoo Lee, Ho-Juhn Song, Jong Sung Koh, Jung-Ho Kim & Phil Ho Lee. (2015) Highly potent and selective pyrazolylpyrimidines as Syk kinase inhibitors. Bioorganic & Medicinal Chemistry Letters 25:20, pages 4441-4446.
Crossref
Crossref
Dave Lengel, Eva Lamm Bergström, Herb Barthlow, Karen Oldman, Helen Musgrove, Alex Harmer, Jean-Pierre Valentin, Paul Duffy, Martin Braddock & Jon Curwen. (2015) Prevention of fostamatinib-induced blood pressure elevation by antihypertensive agents. Pharmacology Research & Perspectives 3:5, pages e00176.
Crossref
Crossref
Michael G. Rolf, Jon O. Curwen, Margaret Veldman‐Jones, Cath Eberlein, Jianyan Wang, Alex Harmer, Caroline J. Hellawell & Martin Braddock. (2015) In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib. Pharmacology Research & Perspectives 3:5.
Crossref
Crossref
Taehun Lee, Jaeyoung Kwon, Dongho Lee & Woongchon Mar. (2015)
Effects of
Cudrania tricuspidata
Fruit Extract and Its Active Compound, 5,7,3′,4′-Tetrahydroxy-6,8-diprenylisoflavone, on the High-Affinity IgE Receptor-Mediated Activation of Syk in Mast Cells
. Journal of Agricultural and Food Chemistry 63:22, pages 5459-5467.
Crossref
Crossref
Ankush Argade, Somasekhar Bhamidipati, Hui Li, David Carroll, Jeffrey Clough, Holger Keim, Catherine Sylvain, Alexander B. Rossi, Christina Coquilla, Sarkiz D. Issakani, Esteban S. Masuda, Donald G. Payan & Rajinder Singh. (2015) Application of cultured human mast cells (CHMC) for the design and structure–activity relationship of IgE-mediated mast cell activation inhibitors. Bioorganic & Medicinal Chemistry Letters 25:10, pages 2117-2121.
Crossref
Crossref
Ankush Argade, Somasekhar Bhamidipati, Hui Li, Catherine Sylvain, Jeffrey Clough, David Carroll, Holger Keim, Sylvia Braselmann, Vanessa Taylor, Haoran Zhao, Ellen Herlaar, Sarkiz D. Issakani, Brian R. Wong, Esteban S. Masuda, Donald G. Payan & Rajinder Singh. (2015) Design, synthesis of diaminopyrimidine inhibitors targeting IgE- and IgG-mediated activation of Fc receptor signaling. Bioorganic & Medicinal Chemistry Letters 25:10, pages 2122-2128.
Crossref
Crossref
Gebhard Thoma, Alexander B. Smith, Maurice J. van Eis, Eric Vangrevelinghe, Joachim Blanz, Reiner Aichholz, Amanda Littlewood-Evans, Christian C. Lee, Hong Liu & Hans-Günter Zerwes. (2015) Discovery and Profiling of a Selective and Efficacious Syk Inhibitor. Journal of Medicinal Chemistry 58:4, pages 1950-1963.
Crossref
Crossref
Sue Ji Lim, Myungsuk Kim, Ahmad Randy & Chu Won Nho. (2015) Inhibitory effect of the branches of Hovenia dulcis Thunb. and its constituent pinosylvin on the activities of IgE-mediated mast cells and passive cutaneous anaphylaxis in mice. Food & Function 6:4, pages 1361-1370.
Crossref
Crossref
Hannah Lim & Young Mi Kim. (2014) Carex pumila Extract Supresses Mast Cell Activation and IgE-Mediated Allergic Response in Mice. Journal of Food Hygiene and Safety 29:4, pages 356-362.
Crossref
Crossref
Michael E. Weinblatt, Mark C. Genovese, Meilien Ho, Sally Hollis, Krystyna Rosiak-Jedrychowicz, Arthur Kavanaugh, David S. Millson, Gustavo Leon, Millie Wang & Désirée van der Heijde. (2014) Effects of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate: Results From a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study. Arthritis & Rheumatology 66:12, pages 3255-3264.
Crossref
Crossref
Mark C. Genovese, Désirée M. van der Heijde, Edward C. Keystone, Alberto J. Spindler, Claude Benhamou, Arthur Kavanaugh, Edward Fudman, Kathy Lampl, Chris O’Brien, Emma L. Duffield, Jeffrey Poiley & Michael E. Weinblatt. (2014) A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of 2 Dosing Regimens of Fostamatinib in Patients with Rheumatoid Arthritis with an Inadequate Response to a Tumor Necrosis Factor-α Antagonist. The Journal of Rheumatology 41:11, pages 2120-2128.
Crossref
Crossref
George D. Kitas, Gabriel Abreu, Krystyna Jedrychowicz-Rosiak, Jeffrey L. Miller, Roumen Nakov, Seva Panfilov, Jiri Vencovsky, Millie Wang, Michael E. Weinblatt & William B. White. (2014) The effects of the spleen tyrosine kinase inhibitor fostamatinib on ambulatory blood pressure in patients with active rheumatoid arthritis: results of the OSKIRA-ABPM (ambulatory blood pressure monitoring) randomized trial. Journal of the American Society of Hypertension 8:11, pages 780-790.
Crossref
Crossref
Florian M.P. Meier & Iain B. McInnes. (2014) Small-molecule therapeutics in rheumatoid arthritis: Scientific rationale, efficacy and safety. Best Practice & Research Clinical Rheumatology 28:4, pages 605-624.
Crossref
Crossref
Hariharan Subramanian, Kshitij Gupta, Narayanan Parameswaran & Hydar Ali. (2014) Regulation of FcϵRI Signaling in Mast Cells by G Protein-coupled Receptor Kinase 2 and Its RH Domain. Journal of Biological Chemistry 289:30, pages 20917-20927.
Crossref
Crossref
Doanh Le Huu, Hiroshi Kimura, Mutsumi Date, Yasuhito Hamaguchi, Minoru Hasegawa, Khang Tran Hau, Manabu Fujimoto, Kazuhiko Takehara & Takashi Matsushita. (2014) Blockade of Syk ameliorates the development of murine sclerodermatous chronic graft-versus-host disease. Journal of Dermatological Science 74:3, pages 214-221.
Crossref
Crossref
Yue Lu, Xian Li, Young Na Park, Okyun Kwon, Donggen Piao, Young-Chae Chang, Cheorl-Ho Kim, Eunkyung Lee, Jong Keun Son & Hyeun Wook Chang. (2014) Britanin Suppresses IgE/Ag-Induced Mast Cell Activation by Inhibiting the Syk Pathway. Biomolecules & Therapeutics 22:3, pages 193-199.
Crossref
Crossref
M Skinner, K Philp, D Lengel, L Coverley, E Lamm Bergström, P Glaves, H Musgrove, H Prior, M Braddock, R Huby, J O Curwen, P Duffy & A R Harmer. (2014) The contribution of VEGF signalling to fostamatinib-induced blood pressure elevation. British Journal of Pharmacology 171:9, pages 2308-2320.
Crossref
Crossref
Lindsey A. MacFarlane & Derrick J. Todd. (2014) Kinase inhibitors: The next generation of therapies in the treatment of rheumatoid arthritis. International Journal of Rheumatic Diseases 17:4, pages 359-368.
Crossref
Crossref
Gebhard Thoma, Joachim Blanz, Peter Bühlmayer, Peter Drückes, Matthias Kittelmann, Alexander B. Smith, Maurice van Eis, Eric Vangrevelinghe, Hans-Günter Zerwes, Jianwei (John) Che, Xiaohui He, Yunho Jin, Christian C. Lee, Pierre-Yves Michellys, Tetsuo Uno & Hong Liu. (2014) Syk inhibitors with high potency in presence of blood. Bioorganic & Medicinal Chemistry Letters 24:10, pages 2278-2282.
Crossref
Crossref
Y. S. Lee, S. Hur & T.-Y. Kim. (2014) Homoisoflavanone prevents mast cell activation and allergic responses by inhibition of Syk signaling pathway. Allergy 69:4, pages 453-462.
Crossref
Crossref
H Patterson, R Nibbs, I McInnes & S Siebert. (2014) Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases. Clinical and Experimental Immunology 176:1, pages 1-10.
Crossref
Crossref
Sergiy A Starosyla. (2014) Pharmacophore approaches in protein kinase inhibitors design. World Journal of Pharmacology 3:4, pages 162.
Crossref
Crossref
Young-Su Yi, Young-Jin Son, Chongsuk Ryou, Gi-Ho Sung, Jong-Hoon Kim & Jae Youl Cho. (2014) Functional Roles of Syk in Macrophage-Mediated Inflammatory Responses. Mediators of Inflammation 2014, pages 1-12.
Crossref
Crossref
Maninder Kaur, Manjinder Singh & Om Silakari. (2013) Inhibitors of switch kinase ‘spleen tyrosine kinase’ in inflammation and immune-mediated disorders: A review. European Journal of Medicinal Chemistry 67, pages 434-446.
Crossref
Crossref
Muhammad Baluom, Elliott B. Grossbard, Tim Mant & David T. W. Lau. (2013) Pharmacokinetics of fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, in healthy human subjects following single and multiple oral dosing in three phase I studies. British Journal of Clinical Pharmacology 76:1, pages 78-88.
Crossref
Crossref
Fernando Padilla, Niala Bhagirath, Shaoqing Chen, Eric Chiao, David M. Goldstein, Johannes C. Hermann, Jonathan Hsu, Joshua J. Kennedy-Smith, Andreas Kuglstatter, Cheng Liao, Wenjian Liu, Lee E. LowrieJr.Jr., Kin Chun Luk, Stephen M. Lynch, John Menke, Linghao Niu, Timothy D. Owens, Counde O-Yang, Aruna Railkar, Ryan C. Schoenfeld, Michelle Slade, Sandra Steiner, Yun-Chou Tan, Armando G. Villaseñor, Ce Wang, Jutta Wanner, Wenwei Xie, Daigen Xu, Xiaohu Zhang, Mingyan Zhou & Matthew C. Lucas. (2013) Pyrrolopyrazines as Selective Spleen Tyrosine Kinase Inhibitors. Journal of Medicinal Chemistry 56:4, pages 1677-1692.
Crossref
Crossref
Maninder Kaur, Archna Kumari, Malkeet Singh Bahia & Om Silakari. (2013) Designing of new multi-targeted inhibitors of spleen tyrosine kinase (Syk) and zeta-associated protein of 70kDa (ZAP-70) using hierarchical virtual screening protocol. Journal of Molecular Graphics and Modelling 39, pages 165-175.
Crossref
Crossref
M. Schaller, J.-D. Studt, J. Voorberg & J. A. Kremer Hovinga. (2018) Acquired thrombotic thrombocytopenic purpura. Hämostaseologie 33:02, pages 121-130.
Crossref
Crossref
Min Jeong Kim, John P. McDaid, Stephen P. McAdoo, Jonathan Barratt, Karen Molyneux, Esteban S. Masuda, Charles D. Pusey & Frederick W. K. Tam. (2012) Spleen Tyrosine Kinase Is Important in the Production of Proinflammatory Cytokines and Cell Proliferation in Human Mesangial Cells following Stimulation with IgA1 Isolated from IgA Nephropathy Patients. The Journal of Immunology 189:7, pages 3751-3758.
Crossref
Crossref
Julian Willibald, Johannes Harder, Konstantin Sparrer, Karl-Klaus Conzelmann & Thomas Carell. (2012) Click-Modified Anandamide siRNA Enables Delivery and Gene Silencing in Neuronal and Immune Cells. Journal of the American Chemical Society 134:30, pages 12330-12333.
Crossref
Crossref
Rajinder Singh, Esteban S. Masuda & Donald G. Payan. (2012) Discovery and Development of Spleen Tyrosine Kinase (SYK) Inhibitors. Journal of Medicinal Chemistry 55:8, pages 3614-3643.
Crossref
Crossref
Dong Ki Park, Wahn Soo Choi & Hye-Jin Park. (2012)
Antiallergic Activity of Novel Isoflavone Methyl-glycosides from
Cordyceps militaris
Grown on Germinated Soybeans in Antigen-Stimulated Mast Cells
. Journal of Agricultural and Food Chemistry 60:9, pages 2309-2315.
Crossref
Crossref
Kui Lea Park, Na Young Ko, Jun Ho Lee, Do Kyun Kim, Hyuk Soon Kim, A-Ram Kim, Erk Her, Bokyung Kim, Hyung Sik Kim, Eun-Yi Moon, Young Mi Kim, Hang-Rae Kim & Wahn Soo Choi. (2011) 4-Chlorotetrazolo[1,5-a]quinoxaline inhibits activation of Syk kinase to suppress mast cells in vitro and mast cell-mediated passive cutaneous anaphylaxis in mice. Toxicology and Applied Pharmacology 257:2, pages 235-241.
Crossref
Crossref
Emily R. Elliott, Jessica A. Van Ziffle, Patrizia Scapini, Brandon M. Sullivan, Richard M. Locksley & Clifford A. Lowell. (2011) Deletion of Syk in Neutrophils Prevents Immune Complex Arthritis. The Journal of Immunology 187:8, pages 4319-4330.
Crossref
Crossref
Muhammad Baluom, Emil Samara, Elliott B. Grossbard & David T.-W. Lau. (2011) Fostamatinib, a Syk-Kinase Inhibitor, Does Not Affect Methotrexate Pharmacokinetics in Patients With Rheumatoid Arthritis. The Journal of Clinical Pharmacology 51:9, pages 1310-1318.
Crossref
Crossref
Ricardo T. Paniagua, David F. Fiorentino, Lorinda Chung & William H. Robinson. (2011) Tyrosine kinases in inflammatory dermatologic disease. Journal of the American Academy of Dermatology 65:2, pages 389-403.
Crossref
Crossref
M.G.H. Stevens, L.J. Peelman, B. De Spiegeleer, A. Pezeshki, G.R. Van De Walle, L. Duchateau & C. Burvenich. (2011) Differential gene expression of the toll-like receptor-4 cascade and neutrophil function in early- and mid-lactating dairy cows. Journal of Dairy Science 94:3, pages 1277-1288.
Crossref
Crossref
Betty Y Chang, Min Huang, Michelle Francesco, Jun Chen, Jeremy Sokolove, Padmaja Magadala, William H Robinson & Joseph J Buggy. (2011) The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Research & Therapy 13:4, pages R115.
Crossref
Crossref
Michael P. Sanderson, Eva Wex, Takeshi Kono, Katsuhiro Uto & Andreas Schnapp. (2010) Syk and Lyn mediate distinct Syk phosphorylation events in FcɛRI-signal transduction: Implications for regulation of IgE-mediated degranulation. Molecular Immunology 48:1-3, pages 171-178.
Crossref
Crossref
J. Michael Bradshaw. (2010) The Src, Syk, and Tec family kinases: Distinct types of molecular switches. Cellular Signalling 22:8, pages 1175-1184.
Crossref
Crossref
David J. Sweeny, Weiqun Li, Jeffrey Clough, Somasekhar Bhamidipati, Rajinder Singh, Gary Park, Muhammad Baluom, Elliott Grossbard & David T.-W. Lau. (2010) Metabolism of Fostamatinib, the Oral Methylene Phosphate Prodrug of the Spleen Tyrosine Kinase Inhibitor R406 in Humans: Contribution of Hepatic and Gut Bacterial Processes to the Overall Biotransformation. Drug Metabolism and Disposition 38:7, pages 1166-1176.
Crossref
Crossref
Mauro Riccaboni, Ivana Bianchi & Paola Petrillo. (2010) Spleen tyrosine kinases: biology, therapeutic targets and drugs. Drug Discovery Today 15:13-14, pages 517-530.
Crossref
Crossref
Francis Antoine, Jamila Ennaciri & Denis Girard. (2010) Syk is a novel target of arsenic trioxide (ATO) and is involved in the toxic effect of ATO in human neutrophils. Toxicology in Vitro 24:3, pages 936-941.
Crossref
Crossref
Jorge Morales-Torres. (2010) R788 (fostamatinib disodium): a novel approach for the treatment of rheumatoid arthritis. International Journal of Clinical Rheumatology 5:1, pages 9-15.
Crossref
Crossref
Deepika Singh, Reema Rani, Resmi Rajendran, Namrata Jit Kaur, Abhinav Pandey, Puneet Chopra, Tarun Jain, Manish Kumar Jain, Sonam Grover, Ranjana Arya & Kulvinder Singh Saini. (2010) Human spleen tyrosine kinase (Syk) recombinant expression systems for high‐throughput assays. Biotechnology Journal 5:2, pages 201-212.
Crossref
Crossref
Michael P. Sanderson, Stephen J. Gelling, Jörg F. Rippmann & Andreas Schnapp. (2010) Comparison of the anti-allergic activity of Syk inhibitors with optimized Syk siRNAs in FcεRI-activated RBL-2H3 basophilic cells. Cellular Immunology 262:1, pages 28-34.
Crossref
Crossref
Kevin S. Currie. 2010.
175
190
.
Jamila Ennaciri & Denis Girard. (2009) IL-4Rα, a New Member that Associates with Syk Kinase: Implication in IL-4-Induced Human Neutrophil Functions. The Journal of Immunology 183:8, pages 5261-5269.
Crossref
Crossref
A D Baudot, P Y Jeandel, X Mouska, U Maurer, S Tartare-Deckert, S D Raynaud, J P Cassuto, M Ticchioni & M Deckert. (2009) The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCδ and proteasome-dependent regulation of Mcl-1 expression. Oncogene 28:37, pages 3261-3273.
Crossref
Crossref
Jie Wan Kim, Jun Ho Lee, Bang Yeon Hwang, Se Hwan Mun, Na Young Ko, Do Kyun Kim, Bokyung Kim, Hyung Sik Kim, Young Mi Kim & Wahn Soo Choi. (2009) Morin inhibits Fyn kinase in mast cells and IgE-mediated type I hypersensitivity response in vivo. Biochemical Pharmacology 77:9, pages 1506-1512.
Crossref
Crossref
Armando G. Villaseñor, Rama Kondru, Hoangdung Ho, Sandra Wang, Eva Papp, David Shaw, Jim W. Barnett, Michelle F. Browner & Andreas Kuglstatter. (2009) Structural Insights for Design of Potent Spleen Tyrosine Kinase Inhibitors from Crystallographic Analysis of Three Inhibitor Complexes. Chemical Biology & Drug Design 73:4, pages 466-470.
Crossref
Crossref
Huan-Zhang Xie, Lin-Li Li, Ji-Xia Ren, Jun Zou, Li Yang, Yu-Quan Wei & Sheng-Yong Yang. (2009) Pharmacophore modeling study based on known Spleen tyrosine kinase inhibitors together with virtual screening for identifying novel inhibitors. Bioorganic & Medicinal Chemistry Letters 19:7, pages 1944-1949.
Crossref
Crossref
Alasdair M. Gilfillan & Juan Rivera. (2009) The tyrosine kinase network regulating mast cell activation. Immunological Reviews 228:1, pages 149-169.
Crossref
Crossref
Shripad S. Bhagwat. (2008) Kinase inhibitors for the treatment of inflammatory and autoimmune disorders. Purinergic Signalling 5:1.
Crossref
Crossref
Charles J. Malemud. (2009) The Discovery of Novel Experimental Therapies for Inflammatory Arthritis. Mediators of Inflammation 2009, pages 1-16.
Crossref
Crossref
Min Li, Paolo Luraghi, Augustin Amour, Xiao-Dong Qian, Paul S. Carter, C.J. Clark, Angela Deakin, Jane Denyer, Clare I. Hobbs, Mark Surby, Vipul K. Patel & Erik M. Schaefer. (2009) Kinetic assay for characterization of spleen tyrosine kinase activity and inhibition with recombinant kinase and crude cell lysates. Analytical Biochemistry 384:1, pages 56-67.
Crossref
Crossref
Peter J. Barnes. 2009. Asthma and COPD. Asthma and COPD
737
749
.
Emily Tsang, Anthony M. Giannetti, David Shaw, Marie Dinh, Joyce K.Y. Tse, Shaan Gandhi, Hoangdung Ho, Sandra Wang, Eva Papp & J. Michael Bradshaw. (2008) Molecular Mechanism of the Syk Activation Switch. Journal of Biological Chemistry 283:47, pages 32650-32659.
Crossref
Crossref
Michael E. Weinblatt, Arthur Kavanaugh, Ruben Burgos-Vargas, Ara H. Dikranian, Gabriel Medrano-Ramirez, Jorge L. Morales-Torres, Frederick T. Murphy, Theresa Kane Musser, Nicholas Straniero, Angela V. Vicente-Gonzales & Elliott Grossbard. (2008) Treatment of rheumatoid arthritis with a syk kinase inhibitor: A twelve-week, randomized, placebo-controlled trial. Arthritis & Rheumatism 58:11, pages 3309-3318.
Crossref
Crossref
Henry E. Speich, Svetozar Grgurevich, Teddi J. Kueter, Angela D. Earhart, Steven M. Slack & Lisa K. Jennings. (2008) Platelets undergo phosphorylation of Syk at Y525/526 and Y352 in response to pathophysiological shear stress. American Journal of Physiology-Cell Physiology 295:4, pages C1045-C1054.
Crossref
Crossref
Akihito Hirabayashi, Harunobu Mukaiyama, Hiroaki Kobayashi, Hiroaki Shiohara, Satoko Nakayama, Motoyasu Ozawa, Eiichi Tsuji, Keiji Miyazawa, Keiko Misawa, Hideki Ohnota & Masayuki Isaji. (2008) Structure–activity relationship studies of imidazo[1,2-c]pyrimidine derivatives as potent and orally effective Syk family kinases inhibitors. Bioorganic & Medicinal Chemistry 16:20, pages 9247-9260.
Crossref
Crossref
Akihito Hirabayashi, Harunobu Mukaiyama, Hiroaki Kobayashi, Hiroaki Shiohara, Satoko Nakayama, Motoyasu Ozawa, Keiji Miyazawa, Keiko Misawa, Hideki Ohnota & Masayuki Isaji. (2008) A novel Syk family kinase inhibitor: Design, synthesis, and structure–activity relationship of 1,2,4-triazolo[4,3-c]pyrimidine and 1,2,4-triazolo[1,5-c]pyrimidine derivatives. Bioorganic & Medicinal Chemistry 16:15, pages 7347-7357.
Crossref
Crossref
Esteban S. Masuda & Jochen Schmitz. (2008) Syk inhibitors as treatment for allergic rhinitis. Pulmonary Pharmacology & Therapeutics 21:3, pages 461-467.
Crossref
Crossref
Jun Ho Lee, Jie Wan Kim, Na Young Ko, Se Hwan Mun, Erk Her, Bo Kyung Kim, Jeung Whan Han, Hoi Young Lee, Michael A. Beaven, Young Mi Kim & Wahn Soo Choi. (2008) Curcumin, a constituent of curry, suppresses IgE-mediated allergic response and mast cell activation at the level of Syk. Journal of Allergy and Clinical Immunology 121:5, pages 1225-1231.
Crossref
Crossref
Alma J. Nauta, Ferdi Engels, Leon M. Knippels, Johan Garssen, Frans P. Nijkamp & Frank A. Redegeld. (2008) Mechanisms of allergy and asthma. European Journal of Pharmacology 585:2-3, pages 354-360.
Crossref
Crossref
Polly R. Pine, Betty Chang, Nathan Schoettler, Mona L. Banquerigo, Su Wang, Angela Lau, Feifei Zhao, Elliott B. Grossbard, Donald G. Payan & Ernest Brahn. (2007) Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. Clinical Immunology 124:3, pages 244-257.
Crossref
Crossref
Venetta Thomas & Erol Fikrig. (2007) Anaplasma phagocytophilum specifically induces tyrosine phosphorylation of ROCK1 during infection. Cellular Microbiology 9:7, pages 1730-1737.
Crossref
Crossref
Yanhong Zhu, Ellen Herlaar, Esteban S. Masuda, Gary R. Burleson, Andrew J. Nelson, Elliott B. Grossbard & George R. Clemens. (2007) Immunotoxicity assessment for the novel Spleen tyrosine kinase inhibitor R406. Toxicology and Applied Pharmacology 221:3, pages 268-277.
Crossref
Crossref
Esteban S. Masuda, Elliott B. Grossbard & Donald G. Payan. (2007) Reply. Journal of Allergy and Clinical Immunology 119:5, pages 1277-1279.
Crossref
Crossref
Giovanni Barbara, Bingxian Wang, Vincenzo Stanghellini, Roberto de Giorgio, Cesare Cremon, Giovanni Di Nardo, Marcello Trevisani, Barbara Campi, Pierangelo Geppetti, Marcello Tonini, Nigel W. Bunnett, David Grundy & Roberto Corinaldesi. (2007) Mast Cell-Dependent Excitation of Visceral-Nociceptive Sensory Neurons in Irritable Bowel Syndrome. Gastroenterology 132:1, pages 26-37.
Crossref
Crossref
Rajinder Singh & Esteban S. Masuda. 2007. Annual Reports in Medicinal Chemistry Volume 42. Annual Reports in Medicinal Chemistry Volume 42
379
391
.
Sylvia Braselmann, Vanessa Taylor, Haoran Zhao, Su Wang, Catherine Sylvain, Muhammad Baluom, Kunbin Qu, Ellen Herlaar, Angela Lau, Chi Young, Brian R. Wong, Scott Lovell, Thomas Sun, Gary Park, Ankush Argade, Stipo Jurcevic, Polly Pine, Rajinder Singh, Elliott B. Grossbard, Donald G. Payan & Esteban S. Masuda. (2006) R406, an Orally Available Spleen Tyrosine Kinase Inhibitor Blocks Fc Receptor Signaling and Reduces Immune Complex-Mediated Inflammation. Journal of Pharmacology and Experimental Therapeutics 319:3, pages 998-1008.
Crossref
Crossref
Peter J. Barnes. (2006) New therapies for asthma. Trends in Molecular Medicine 12:11, pages 515-520.
Crossref
Crossref
J.C.W. Edwards, G. Cambridge & M.J. Leandro. (2006) B cell depletion therapy in rheumatic disease. Best Practice & Research Clinical Rheumatology 20:5, pages 915-928.
Crossref
Crossref
Hoon-Suk Cha, David L. Boyle, Tomoyuki Inoue, Reineke Schoot, Paul P. Tak, Polly Pine & Gary S. Firestein. (2006) A Novel Spleen Tyrosine Kinase Inhibitor Blocks c-Jun N-Terminal Kinase-Mediated Gene Expression in Synoviocytes. Journal of Pharmacology and Experimental Therapeutics 317:2, pages 571-578.
Crossref
Crossref
Jonathan C. W. Edwards & Geraldine Cambridge. (2006) B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nature Reviews Immunology 6:5, pages 394-403.
Crossref
Crossref
Andrea Rinaldi, Ivo Kwee, Monica Taborelli, Cristina Largo, Silvia Uccella, Vittoria Martin, Giulia Poretti, Gianluca Gaidano, Giuseppe Calabrese, Giovanni Martinelli, Luca Baldini, Giancarlo Pruneri, Carlo Capella, Emanuele Zucca, Finbarr E. Cotter, Juan C. Cigudosa, Carlo V. Catapano, Maria G. Tibiletti & Francesco Bertoni. (2005) Genomic and expression profiling identifies the B‐cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. British Journal of Haematology 132:3, pages 303-316.
Crossref
Crossref
Shigeki Matsubara, Guiming Li, Katsuyuki Takeda, Joan E. Loader, Polly Pine, Esteban S. Masuda, Nobuaki Miyahara, Satoko Miyahara, Joseph J. Lucas, Azzeddine Dakhama & Erwin W. Gelfand. (2006) Inhibition of Spleen Tyrosine Kinase Prevents Mast Cell Activation and Airway Hyperresponsiveness. American Journal of Respiratory and Critical Care Medicine 173:1, pages 56-63.
Crossref
Crossref
g. barbara, v. stanghellini, r. de giorgio & r. corinaldesi. (2006) Functional gastrointestinal disorders and mast cells: implications for therapy. Neurogastroenterology and Motility 18:1, pages 6-17.
Crossref
Crossref
Peter J. Barnes. (2006) Novel signal transduction modulators for the treatment of airway diseases. Pharmacology & Therapeutics 109:1-2, pages 238-245.
Crossref
Crossref
T. Yamada, N. Takahashi, H. Sunaga, N. Narita, H. Yamamoto & S. Fujieda. (2005) Roles of protein tyrosine kinase Syk in nasal polyps. Clinical <html_ent glyph="@amp;" ascii="&"/> Experimental Allergy Reviews 5:2, pages 72-76.
Crossref
Crossref
Eli O. Meltzer, Robert B. Berkowitz & Elliott B. Grossbard. (2005) An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment. Journal of Allergy and Clinical Immunology 115:4, pages 791-796.
Crossref
Crossref